238 related articles for article (PubMed ID: 30709841)
21. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion.
Linard B; Bézieau S; Benlalam H; Labarrière N; Guilloux Y; Diez E; Jotereau F
J Immunol; 2002 May; 168(9):4802-8. PubMed ID: 11971032
[TBL] [Abstract][Full Text] [Related]
22. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB
Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724
[TBL] [Abstract][Full Text] [Related]
23. Targeting a neoantigen derived from a common
Hsiue EH; Wright KM; Douglass J; Hwang MS; Mog BJ; Pearlman AH; Paul S; DiNapoli SR; Konig MF; Wang Q; Schaefer A; Miller MS; Skora AD; Azurmendi PA; Murphy MB; Liu Q; Watson E; Li Y; Pardoll DM; Bettegowda C; Papadopoulos N; Kinzler KW; Vogelstein B; Gabelli SB; Zhou S
Science; 2021 Mar; 371(6533):. PubMed ID: 33649166
[No Abstract] [Full Text] [Related]
24. Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen.
Novellino L; Renkvist N; Rini F; Mazzocchi A; Rivoltini L; Greco A; Deho P; Squarcina P; Robbins PF; Parmiani G; Castelli C
J Immunol; 2003 Jun; 170(12):6363-70. PubMed ID: 12794170
[TBL] [Abstract][Full Text] [Related]
25. Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma.
Tan Q; Zhang C; Yang W; Liu Y; Heyilimu P; Feng D; Xing L; Ke Y; Lu Z
J Immunother Cancer; 2019 Aug; 7(1):232. PubMed ID: 31462302
[TBL] [Abstract][Full Text] [Related]
26. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
[TBL] [Abstract][Full Text] [Related]
27. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D.
Sim MJW; Lu J; Spencer M; Hopkins F; Tran E; Rosenberg SA; Long EO; Sun PD
Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12826-12835. PubMed ID: 32461371
[TBL] [Abstract][Full Text] [Related]
28. Structural basis for T cell recognition of cancer neoantigens and implications for predicting neoepitope immunogenicity.
Mariuzza RA; Wu D; Pierce BG
Front Immunol; 2023; 14():1303304. PubMed ID: 38045695
[TBL] [Abstract][Full Text] [Related]
29. A Comprehensive Survey of Genomic Alterations in Gastric Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets.
Chen C; Zhou Q; Wu R; Li B; Chen Q; Zhang X; Shi C
Biomed Res Int; 2019; 2019():2183510. PubMed ID: 31781598
[TBL] [Abstract][Full Text] [Related]
30. T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes.
Mennonna D; Maccalli C; Romano MC; Garavaglia C; Capocefalo F; Bordoni R; Severgnini M; De Bellis G; Sidney J; Sette A; Gori A; Longhi R; Braga M; Ghirardelli L; Baldari L; Orsenigo E; Albarello L; Zino E; Fleischhauer K; Mazzola G; Ferrero N; Amoroso A; Casorati G; Parmiani G; Dellabona P
Gut; 2017 Mar; 66(3):454-463. PubMed ID: 26681737
[TBL] [Abstract][Full Text] [Related]
31. T-cell Receptor Gene Therapy Clinically Targeting a TP53 Public Neoantigen.
Klebanoff CA
Cancer Immunol Res; 2022 Aug; 10(8):919. PubMed ID: 35767244
[TBL] [Abstract][Full Text] [Related]
32. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53.
Umano Y; Tsunoda T; Tanaka H; Matsuda K; Yamaue H; Tanimura H
Br J Cancer; 2001 Apr; 84(8):1052-7. PubMed ID: 11308253
[TBL] [Abstract][Full Text] [Related]
33. Histocompatibility leukocyte antigen-A2402-restricted cytotoxic T lymphocytes recognizing adenocarcinoma in tumor-infiltrating lymphocytes of patients with colon cancer.
Gohara R; Nakao M; Ogata Y; Isomoto H; Oizumi K; Itoh K
Jpn J Cancer Res; 1997 Feb; 88(2):198-204. PubMed ID: 9119749
[TBL] [Abstract][Full Text] [Related]
34. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
35. An effective mouse model for adoptive cancer immunotherapy targeting neoantigens.
Hanada KI; Yu Z; Chappell GR; Park AS; Restifo NP
JCI Insight; 2019 May; 4(10):. PubMed ID: 31092734
[TBL] [Abstract][Full Text] [Related]
36. Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1.
Maccalli C; Di Cristanziano V; Fodale V; Corsi D; D'Agostino G; Petrangeli V; Laurenti L; Guida S; Mazzocchi A; Arienti F; Perrone MP; Castelli C; Rivoltini L; Zagonel V; Tartaglia M; Parmiani G; Belardelli F
Clin Cancer Res; 2008 Nov; 14(22):7292-303. PubMed ID: 18974390
[TBL] [Abstract][Full Text] [Related]
37. T-cell response to p53 tumor-associated antigen in patients with colorectal carcinoma.
Bueter M; Gasser M; Schramm N; Lebedeva T; Tocco G; Gerstlauer C; Grimm M; Nichiporuk E; Thalheimer A; Thiede A; Meyer D; Benichou G; Waaga-Gasser AM
Int J Oncol; 2006 Feb; 28(2):431-8. PubMed ID: 16391798
[TBL] [Abstract][Full Text] [Related]
38. [A method of screening highly common neoantigens with immunogenicity in colorectal cancer based on public somatic mutation library].
Qin LL; Li YJ; Liang ZR; Dai L; Li WH; Chen C; Huang YL; Zhang L; Liu SM; Qiu S; Ge YP; Peng WT; Lin XX; Zhang XQ; Dong X; Li B
Yi Chuan; 2020 Jun; 42(6):599-612. PubMed ID: 32694118
[TBL] [Abstract][Full Text] [Related]
39. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.
Cohen CJ; Gartner JJ; Horovitz-Fried M; Shamalov K; Trebska-McGowan K; Bliskovsky VV; Parkhurst MR; Ankri C; Prickett TD; Crystal JS; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
J Clin Invest; 2015 Oct; 125(10):3981-91. PubMed ID: 26389673
[TBL] [Abstract][Full Text] [Related]
40. P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs.
Zhao Y; Li Y; Sheng J; Wu F; Li K; Huang R; Wang X; Jiao T; Guan X; Lu Y; Chen X; Luo Z; Zhou Y; Hu H; Liu W; Du B; Miao S; Cai J; Wang L; Zhao H; Ying J; Bi X; Song W
J Exp Clin Cancer Res; 2019 Aug; 38(1):379. PubMed ID: 31455383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
